Immucell (ICCC) Non Operating Income (2010 - 2026)
Immucell's (ICCC) quarterly Non Operating Income came in at -$2.8 million in Q4 2025, down 2665.64% YoY from $108662.0 in Q4 2024, and down 1694.38% on a QoQ basis from -$155367.0 in Q3 2025.
Immucell (ICCC) Non Operating Income (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 6 years of Non Operating Income data on file, last reported at -$2.8 million in Q4 2025.
- Quarterly Non Operating Income fell 2665.64% year-over-year to -$2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.7 million (down 428.77% YoY) and the FY2025 annual result came in at -$2.7 million, down 428.77% from the prior year.
- Non Operating Income eased to -$2.8 million in Q4 2025, from -$155367.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $331263.0 in Q1 2025 to a low of -$2.8 million in Q4 2025.
- A 3-year average of -$307488.7 and a median of -$130220.5 in 2023 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 342.73% in 2025, down 2665.64% in 2025.
- Tracing ICCC's Non Operating Income over 3 years: stood at -$134985.0 in 2023, then increased by 25.32% to -$100804.0 in 2024, then slumped by 2665.64% to -$2.8 million in 2025.
- The last three Non Operating Income figures came in at -$2.8 million (Q4 2025), -$155367.0 (Q3 2025), and -$65778.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | -54,328.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54,328.00 |
| Dec 31, 2025 | -2.79 Mn |
| Sep 30, 2025 | -155,367.00 |
| Jun 30, 2025 | -65,778.00 |
| Mar 31, 2025 | 331,263.00 |
| Dec 31, 2024 | -100,804.00 |
| Sep 30, 2024 | -125,456.00 |
| Jun 30, 2024 | -143,679.00 |
| Mar 31, 2024 | -136,476.00 |
| Dec 31, 2023 | -134,985.00 |
| Sep 30, 2023 | 244,275.00 |
| Sep 30, 2012 | 8,265.00 |
| Jun 30, 2012 | -10,364.00 |
| Mar 31, 2012 | -10,509.00 |
| Dec 31, 2011 | -120,925.00 |
| Sep 30, 2011 | 18,539.00 |
| Jun 30, 2011 | -23,793.00 |
| Mar 31, 2011 | -14,638.00 |
| Dec 31, 2010 | -10,592.00 |
| Sep 30, 2010 | -3,040.00 |